A number of recent trials have explored potential strategies for using immunotherapy in chronic lymphocytic leukemia (CLL).

Shares of Cartesian Therapeutics climbed after the company announced positive results in a phase 2b trial of its lead cell-therapy candidate. The stock was up 8.3% to $15.60 in morning trading Tuesday ...

Addressing the accessibility and high costs of chimeric antibody receptor (CAR) T-cell and bispecific therapies is crucial ...

The global CD Antigen Cancer Therapy Market is valued at USD 27.5 Billion in 2024 and is projected to reach a value of USD 54 ...

Shares of Legend Biotech Co. (NASDAQ:LEGN – Get Free Report) hit a new 52-week low during mid-day trading on Monday . The company traded as low as $29.31 and last traded at $30.15, with a volume of ...

Joshua Oduyemi is pioneering a global movement in the fight against cancer and autoimmune diseases through its cutting-edge ...

Equities research analysts at StockNews.com started coverage on shares of Sorrento Therapeutics (NASDAQ:SRNE – Get Free Report) in a report released on Tuesday. The firm set a “hold” rating on the ...

CAR-T cell therapy is a breakthrough in cancer immunotherapy. The treatment is available in India at a fraction of the cost abroad. Among the many emerging treatments for cancer, there's one called ...

Fate Therapeutics, Inc.’s FATE share price has surged by 10.29%, which has investors questioning if this is right time to ...